Evaluation of toxicity profile of zoledronic acid in Wistar rat: A sub-chronic toxicity study

Internet Journal of Toxicology

Volumn 6, Issue 2, 2009, Pages

  Chaudhary, Manu ^a   Tamta, Anupama ^a   Sehgal, Rajesh ^a  

^a Venus Medicine Research Centre   (India)

Author keywords

Bisphosphonate; Bone resorption; Osteoporosis; Subchronic toxicity; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; MALE; MORTALITY; NONHUMAN; RAT;

RATTUS; RATTUS NORVEGICUS;

EID: 77953389911     PISSN: None     EISSN: 15593916     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Adami, S., Bevilacqua, M., Broggini, M., Filipponi, P., Ortolani, S., Palummeri, E., Ulivieri, F., Nannipieri, F., and Braga, V. (2002). Short-term intravenous therapy with Neridronate in Paget's disease. Clin Exp Rheumatol 20, 55-8. (s)
2. Andrew, S., Andrew, R., Nola, K., Christina, R., Serge, C., Sanela, B., Terry, N., Michael, C., Horst, S., Kevin, L. (2008) Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. BMC Clinical Pharmacology, 8, 2. (s)
3. Amanat, N., McDonald., M, Godfrey., C, Bilston, L.(2007). Little DOptimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.J Bone Miner Res. 22(6), 867-76. (s)
4. Aparicio, A., Gardner, A., Tu, Y., Savage, A., Berenson, J., and Lichtenstein, A. (1998). In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12, 220-9. (s)
5. Berenson, J. R. (2005). Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 10, 52-62. (s)
6. Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., and Cummings, S. R. (2007). Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356, 1809-22. (s)
7. Body, J. J., Lortholary, A., Romieu, G., Vigneron, A. M., and Ford, J. (1999). A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14, 1557-61. (s)
8. Boutsen, Y., Jamart, J., Esselinckx, W., and Devogelaer, J. P. (2001). Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16, 104-12. (s)
9. Conte, P., and Guarneri, V. (2004). Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 9 Suppl 4, 28-37. (s)
10. Coukell, A. J., and Markham, A. (1998). Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 12, 149-68. (s)
11. de Nijs, R. N., and Westgeest, A. A. (2007). Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357, 711; author reply 714-5. (s)
12. Gouin, F., Ory, B., Redini, F., and Heymann, D. (2006). Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 119, 980-4. (s)
13. Grbic, J. T., Landesberg, R., Lin, S. Q., Mesenbrink, P., Reid, I. R., Leung, P. C., Casas, N., Recknor, C. P., Hua, Y., Delmas, P. D., and Eriksen, E. F. (2008). Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139, 32-40. (s)
14. Kimmel, D. B. (2007). Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 86, 1022-33. (s)
15. Lacerna, L., and Hohneker, J. (2003). Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol 30, 150-60. (s)
16. Lipton, A., Small, E., Saad, F., Gleason, D., Gordon, D., Smith, M., Rosen, L., Kowalski, M. O., Reitsma, D., and Seaman, J. (2002). The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 20 Suppl 2, 45-54. (s)
17. Lyles, K. W., Colon-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., and Boonen, S. (2007). Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357, 1799-809. (s)
18. Maclaughlin, E. J., Raehl, C. L., and Reilly, C. (2008). Celiac disease and osteoporosis. Am J Health Syst Pharm 65, 1601-1602. (s)
19. MacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., Desai, S. B., Zhou, A., Chen, S., Carter, J., Tringale, C., Valentine, D., Johnsen, B., and Grossman, J. (2008). Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148, 197-213. (s)
20. Major, P. (2002). The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 7, 481-91. (s)
21. Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J. P., Kaufman, J. M., Jaeger, P., Body, J. J., Brandi, M. L., Broell, J., Di Micco, R., Genazzani, A. R., Felsenberg, D., Happ, J., Hooper, M. J., Ittner, J., Leb, G., Mallmin, H., Murray, T., Ortolani, S., Rubinacci, A., Saaf, M., Samsioe, G., Verbruggen, L., and Meunier, P. J. (2002). Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346, 653-61. (s)
22. Suzuki, A., Sekiguchi, S., Asano, S., and Itoh, M. (2008). Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis. J Pharmacol Sci 106, 530-5. (s)
23. Weiss, H. M., Pfaar, U., Schweitzer, A., Wiegand, H., Skerjanec, A., and Schran, H. (2008). Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 36, 2043-9. (s)
24. Woolf, A. D., and Akesson, K. (2003). Preventing fractures in elderly people. Bmj 327, 89-95. (s)